Pharmacological Treatment of Early-Onset Schizophrenia: A Critical
                    Review, Evidence-Based Clinical Guidance and Unmet Needs

Javier-David Lopez-Morinigo; Stefan Leucht; Celso Arango

doi:10.1055/a-1854-0185

Pharmacopsychiatry, Table of Contents

CC BY-NC-ND 4.0 · Pharmacopsychiatry 2022; 55(05): 233-245
DOI: 10.1055/a-1854-0185

Review

Pharmacological Treatment of Early-Onset Schizophrenia: A Critical Review, Evidence-Based Clinical Guidance and Unmet Needs

Authors

Javier-David Lopez-Morinigo

¹Department of Child and Adolescent Psychiatry, Institute of Psychiatry and Mental Health, Hospital General Universitario Gregorio Marañón, IiSGM, CIBERSAM, School of Medicine, Universidad Complutense, Madrid, Spain

²Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Madrid, Spain
Stefan Leucht‡

³Department of Psychiatry and Psychotherapy, School of Medicine, Technical University of Munich, Ismaninger Straße 22, Munich, Germany
Celso Arango‡

¹Department of Child and Adolescent Psychiatry, Institute of Psychiatry and Mental Health, Hospital General Universitario Gregorio Marañón, IiSGM, CIBERSAM, School of Medicine, Universidad Complutense, Madrid, Spain

²Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Madrid, Spain

Abstract

Early-onset schizophrenia (EOS) – onset before age 18 – is linked with great disease burden and disability. Decision-making for EOS pharmacological treatment may be challenging due to conflicting information from evidence and guidelines and unidentified care needs may remain unmet.

We searched for systematic reviews, meta-analyses and umbrella reviews of EOS pharmacological treatment published in PubMed over the past 10 years and selected five clinical guidelines from Europe, North-America and Australia. Based on predefined outcomes, we critically compared the evidence supporting EOS-approved drugs in Europe and/or North-America with guidelines recommendations. We also evaluated the coverage of these outcomes to identify unmet needs.

One systematic review, nine meta-analyses and two umbrella reviews (k=203 trials, N=81,289 participants, including duplicated samples across selected articles) were retrieved. Evidence supported the efficacy of aripiprazole, clozapine, haloperidol, lurasidone, molindone, olanzapine, quetiapine, risperidone and paliperidone in EOS, all of which obtained approval for EOS either in Europe and/or in North-America. Cognition, functioning and quality of life, suicidal behaviour and mortality and services utilisation and cost-effectiveness were poorly covered/uncovered.

Among the antipsychotics approved for EOS, aripiprazole, lurasidone, molindone, risperidone, paliperidone and quetiapine emerged as efficacious and comparably safe options. Olanzapine is known for a high risk of weight gain and haloperidol for extrapyramidal side-effects. Treatment-resistant patients should be offered clozapine. Future long-term trials looking at cognition, functioning, quality of life, suicidal behaviour, mortality, services utilisation and cost-effectiveness are warranted. Closer multi-agency collaboration may bridge the gap between evidence, guidelines and approved drugs.

Key words

Child - adolescent - schizophrenia - antipsychotics - metanalysis - systematic review

Full Text

References

References
1 Masi G, Liboni F. Management of schizophrenia in children and adolescents: Focus on pharmacotherapy. Drugs 2011; 71: 179-208
2 James A, Clacey J, Seagroatt V. et al. Adolescent inpatient psychiatric admission rates and subsequent one-year mortality in England: 1998-2004. J Child Psychol Psychiatry 2010; 51: 1395-1404
3 Piovani D, Clavenna A, Bonati M. Prescription prevalence of psychotropic drugs in children and adolescents: An analysis of international data. Eur J Clin Pharmacol 2019; 75: 1333-1346
4 Díaz-Caneja CM, Pina-Camacho L, Rodríguez-Quiroga A. et al. Predictors of outcome in early-onset psychosis: A systematic review. NPJ Schizophr 2015; 1: 14005
5 GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet 2018; 392: 1789-1858
6 He H, Liu Q, Li N. et al. Trends in the incidence and DALYs of schizophrenia at the global, regional and national levels: Results from the Global Burden of Disease Study 2017. Epidemiol Psychiatr Sci 2020; 29: e91
7 Hjorthøj C, Stürup AE, McGrath JJ. et al. Years of potential life lost and life expectancy in schizophrenia: A systematic review and meta-analysis. Lancet Psychiatry 2017; 4: 295-301
8 Laursen TM, Nordentoft M, Mortensen PB. Excess early mortality in schizophrenia. Annu Rev Clin Psychol 2014; 10: 425-448
9 Saha S, Chant D, McGrath J. A systematic review of mortality in schizophrenia: Is the differential mortality gap worsening over time?. Arch Gen Psychiatry 2007; 64: 1123-1131
10 Lora A, Kohn R, Levav I. et al. Service availability and utilization and treatment gap for schizophrenic disorders: A survey in 50 low- and middle-income countries. Bull World Health Organ 2012; 90: 47-54 54A-54B
11 Chong HY, Teoh SL, Wu DB-C. et al. Global economic burden of schizophrenia: A systematic review. Neuropsychiatr Dis Treat 2016; 12: 357-373
12 Arango C, Díaz-Caneja CM, McGorry PD. et al. Preventive strategies for mental health. Lancet Psychiatry 2018; 5: 591-604
13 Correll CU, Galling B, Pawar A. et al. Comparison of early intervention services vs treatment as usual for early-phase psychosis: A systematic review, meta-analysis, and meta-regression. JAMA Psychiatry 2018; 75: 555-565
14 Food and Drugs Administration (FDA). [https://www.fda.gov/drugs] Accessed 5 Nov 2021
15 European Medicines Agency (EMA). [https://www.ema.europa.eu] Accessed 5 Nov 2021
16 Braüner JV, Johansen LM, Roesbjerg T. et al. Off-label prescription of psychopharmacological drugs in child and adolescent psychiatry. J Clin Psychopharmacol 2016; 36: 500-507
17 Correll CU, Cortese S, Croatto G. et al. Efficacy and acceptability of pharmacological, psychosocial, and brain stimulation interventions in children and adolescents with mental disorders: An umbrella review. World Psychiatry 2021; 20: 244-275
18 Solmi M, Fornaro M, Ostinelli EG. et al. Safety of 80 antidepressants, antipsychotics, anti-attention-deficit/hyperactivity medications and mood stabilizers in children and adolescents with psychiatric disorders: A large scale systematic meta-review of 78 adverse effects. World Psychiatry 2020; 19: 214-232
19 World Health Organization, WHO. The ICD-10 classification of mental and behavioural disorders: diagnostic criteria for research. Geneva: World Health Organization; 1993
20 American Psychiatric Association. American Psychiatric Association, Hrsg. Diagnostic and statistical manual of mental disorders: DSM-IV-TR. 4th ed., text revision. Washington, DC: American Psychiatric Association; 2000
21 American Psychiatric Association. American Psychiatric Association, Hrsg. Diagnostic and statistical manual of mental disorders: DSM-5. 5th ed. Washington, D.C: American Psychiatric Association; 2013
22 Arango C, Ng-Mak D, Finn E. et al. Lurasidone compared to other atypical antipsychotic monotherapies for adolescent schizophrenia: A systematic literature review and network meta-analysis. Eur Child Adolesc Psychiatry 2020; 29: 1195-1205
23 Cohen D, Bonnot O, Bodeau N. et al. Adverse effects of second-generation antipsychotics in children and adolescents: A Bayesian meta-analysis. J Clin Psychopharmacol 2012; 32: 309-316
24 Harvey RC, James AC, Shields GE. A systematic review and network meta-analysis to assess the relative efficacy of antipsychotics for the treatment of positive and negative symptoms in early-onset schizophrenia. CNS Drugs 2016; 30: 27-39
25 Krause M, Zhu Y, Huhn M. et al. Efficacy, acceptability, and tolerability of antipsychotics in children and adolescents with schizophrenia: A network meta-analysis. Eur Neuropsychopharmacol 2018; 28: 659-674
26 Kumar A, Datta SS, Wright SD. et al. Atypical antipsychotics for psychosis in adolescents. Cochrane Database Syst Rev 2013; CD009582
27 Pagsberg AK, Tarp S, Glintborg D. et al. Acute antipsychotic treatment of children and adolescents with schizophrenia-spectrum disorders: A systematic review and network meta-analysis. J Am Acad Child Adolesc Psychiatry 2017; 56: 191-202
28 Sarkar S, Grover S. Antipsychotics in children and adolescents with schizophrenia: A systematic review and meta-analysis. Indian J Pharmacol 2013; 45: 439-446
29 Xia L, Li W-Z, Liu H-Z. et al. Olanzapine versus risperidone in children and adolescents with pychosis: A meta-analysis of randomized controlled trials. J Child Adolesc Psychopharmacol 2018; 28: 244-251
30 Pringsheim T, Lam D, Ching H. et al. Metabolic and neurological complications of second-generation antipsychotic use in children: A systematic review and meta-analysis of randomized controlled trials. Drug Saf 2011; 34: 651-668
31 Druyts E, Zoratti MJ, Toor K. et al. Prolactin-related adverse events and change in prolactin levels in pediatric patients given antipsychotics for schizophrenia and schizophrenia spectrum disorders: A systematic review. BMC Pediatr 2016; 16: 181
32 German Association for Psychiatry, Psychotherapy and Psychosomatics. DGPPN e.V. (ed.) for the Guideline Group: S3 Guideline for Schizophrenia. 2019
33 Taylor D, Barnes TRE, Young AH. The Maudsley prescribing guidelines in psychiatry. 13th edition Hoboken, NJ: Wiley; 2019
34 McClellan J, Stock S. American Academy of Child and Adolescent Psychiatry (AACAP) Committee on Quality Issues (CQI). Practice parameter for the assessment and treatment of children and adolescents with schizophrenia. J Am Acad Child Adolesc Psychiatry 2013; 52: 976-990
35 Abidi S, Mian I, Garcia-Ortega I. et al. Canadian guidelines for the pharmacological treatment of schizophrenia spectrum and other psychotic disorders in children and youth. Can J Psychiatry 2017; 62: 635-647
36 Australian Clinical Guidelines for Early Psychosis. 2016
37 Institute of Medicine (US) Committee on Standards for Developing Trustworthy Clinical Practice Guidelines. Clinical Practice Guidelines We Can Trust. Washington (DC): National Academies Press (US); 2011
38 Devoe DJ, Farris MS, Townes P. et al. Interventions and transition in youth at risk of psychosis: A systematic review and meta-analyses. J Clin Psychiatry 2020; 81 17r12053
39 Mei C, van der Gaag M, Nelson B. et al. Preventive interventions for individuals at ultra high risk for psychosis: An updated and extended meta-analysis. Clin Psychol Rev 2021; 86: 102005
40 NICE. Psychosis and schizophrenia in children and young people: Recognition and management. 2013
41 Arango C, Giráldez M, Merchán-Naranjo J. et al. Second-generation antipsychotic use in children and adolescents: A six-month prospective cohort study in drug-naïve patients. J Am Acad Child Adolesc Psychiatry 2014; 53: 1179-1190 1190.e1-4
42 Arango C, Robles O, Parellada M. et al. Olanzapine compared to quetiapine in adolescents with a first psychotic episode. Eur Child Adolesc Psychiatry 2009; 18: 418-428
43 Garcia-Amador M, Merchán-Naranjo J, Tapia C. et al. Neurological adverse effects of antipsychotics in children and adolescents. J Clin Psychopharmacol 2015; 35: 686-693
44 Brown FE, David AS.. Drugs do not work if patients do not take them. Eur Neuropsychopharmacol 2021; 53: 47-48
45 Zhang J-P, Gallego JA, Robinson DG. et al. Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: A systematic review and meta-analysis. Int J Neuropsychopharmacol 2013; 16: 1205-1218
46 Schneider C, Corrigall R, Hayes D. et al. Systematic review of the efficacy and tolerability of clozapine in the treatment of youth with early onset schizophrenia. Eur Psychiatry 2014; 29: 1-10
47 Howes OD, McCutcheon R, Agid O. et al. Treatment-resistant schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) working group consensus guidelines on diagnosis and terminology. Am J Psychiatry 2017; 174: 216-229
48 Huhn M, Nikolakopoulou A, Schneider-Thoma J. et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: A systematic review and network meta-analysis. Lancet 2019; 394: 939-951
49 Ellul P, Delorme R, Cortese S. Metformin for weight gain associated with second-generation antipsychotics in children and adolescents: A systematic review and meta-analysis. CNS Drugs 2018; 32: 1103-1112
50 Jauhar S, Veronese M, Nour MM. et al. Determinants of treatment response in first-episode psychosis: An 18F-DOPA PET study. Mol Psychiatry 2019; 24: 1502-1512
51 Balijepalli C, Druyts E, Zoratti MJ. et al. Change in prolactin levels in pediatric patients given antipsychotics for schizophrenia and schizophrenia spectrum disorders: A network meta-analysis. Schizophr Res Treatment 2018; 2018: 1543034
52 Leucht S, Bauer S, Siafis S. et al. Examination of dosing of antipsychotic drugs for relapse prevention in patients with stable schizophrenia: A meta-analysis. JAMA Psychiatry 2021;
53 Hiemke C, Bergemann N, Clement HW. et al. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: Update 2017. Pharmacopsychiatry 2018; 51: 9-62
54 Whitney Z, Boyda HN, Procyshyn RM. et al. Therapeutic drug levels of second generation antipsychotics in youth: A systematic review. J Child Adolesc Psychopharmacol 2015; 25: 234-245
55 Gerlach M, Egberts K, Dang S-Y. et al. Therapeutic drug monitoring as a measure of proactive pharmacovigilance in child and adolescent psychiatry. Expert Opin Drug Saf 2016; 15: 1477-1482
56 Kloosterboer SM, Vierhout D, Stojanova J. et al. Psychotropic drug concentrations and clinical outcomes in children and adolescents: A systematic review. Expert Opin Drug Saf 2020; 19: 873-890
57 Fekete S, Hiemke C, Gerlach M. Dose-related concentrations of neuroactive/psychoactive drugs expected in blood of children and adolescents. Ther Drug Monit 2020; 42: 315-324
58 Murray RM, Quattrone D, Natesan S. et al. Should psychiatrists be more cautious about the long-term prophylactic use of antipsychotics?. Br J Psychiatry 2016; 209: 361-365
59 Correll CU, Rubio JM, Kane JM. What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia?. World Psychiatry 2018; 17: 149-160
60 Højlund M, Kemp AF, Haddad PM. et al. Standard versus reduced dose of antipsychotics for relapse prevention in multi-episode schizophrenia: A systematic review and meta-analysis of randomised controlled trials. Lancet Psychiatry 2021; 8: 471-486
61 Kane JM, Correll CU. Optimizing treatment choices to improve adherence and outcomes in schizophrenia. J Clin Psychiatry 2019; 80 IN18031AH1C
62 Kishimoto T, Hagi K, Kurokawa S. et al. Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: A systematic review and comparative meta-analysis of randomised, cohort, and pre-post studies. Lancet Psychiatry 2021; 8: 387-404
63 David AS. Insight and psychosis. Br J Psychiatry 1990; 156: 798-808
64 David AS. Insight and psychosis: The next 30 years. Br J Psychiatry 2019; 1-3
65 Pijnenborg GHM, van Donkersgoed RJM, David AS. et al. Changes in insight during treatment for psychotic disorders: A meta-analysis. Schizophr Res 2013; 144: 109-117
66 Pijnenborg GHM, Timmerman ME, Derks EM. et al. Differential effects of antipsychotic drugs on insight in first episode schizophrenia: Data from the European First-Episode Schizophrenia Trial (EUFEST). Eur Neuropsychopharmacol 2015; 25: 808-816
67 Lopez-Morinigo J-D, Ajnakina O, Martínez AS-E. et al. Can metacognitive interventions improve insight in schizophrenia spectrum disorders? A systematic review and meta-analysis. Psychol Med 2020; 50: 2289-2301
68 Németh G, Dombi ZB, Laszlovszky I. et al. Addressing negative symptoms of schizophrenia pharmacologically with cariprazine: Evidence from clinical trials, a real-world study, and clinical cases. Expert Opin Pharmacother 2021; 1-2
69 Bugarski-Kirola D, Arango C, Fava M. et al. Pimavanserin for negative symptoms of schizophrenia: Results from the ADVANCE phase 2 randomised, placebo-controlled trial in North America and Europe. Lancet Psychiatry 2022; 9: 46-58
70 Gentile S. Clinical usefulness of second-generation antipsychotics in treating children and adolescents diagnosed with bipolar or schizophrenic disorders. Paediatr Drugs 2011; 13: 291-302
71 Sommer IE, Bearden CE, van Dellen E. et al. Early interventions in risk groups for schizophrenia: What are we waiting for?. NPJ Schizophr 2016; 2: 16003
72 Murai T, Nakako T, Ikeda K. et al. Lack of dopamine D4 receptor affinity contributes to the procognitive effect of lurasidone. Behav Brain Res 2014; 261: 26-30
73 Loebel A, Cucchiaro J, Xu J. et al. Effectiveness of lurasidone vs. quetiapine XR for relapse prevention in schizophrenia: A 12-month, double-blind, noninferiority study. Schizophr Res 2013; 147: 95-102
74 Miron O, Yu K-H, Wilf-Miron R. et al. Suicide rates among adolescents and young adults in the United States, 2000-2017. JAMA 2019; 321: 2362
75 Palmer BA, Pankratz VS, Bostwick JM. The lifetime risk of suicide in schizophrenia: A reexamination. Arch Gen Psychiatry 2005; 62: 247-253
76 Tondo L, Baldessarini RJ. Suicidal behavior in mood disorders: Response to pharmacological treatment. Curr Psychiatry Rep 2016; 18: 88
77 Meltzer HY, Alphs L, Green AI. et al. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry 2003; 60: 82-91
78 Papola D, Ostuzzi G, Gastaldon C. et al. Antipsychotic use and risk of life-threatening medical events: Umbrella review of observational studies. Acta Psychiatr Scand 2019; 140: 227-243
79 Kawohl W, Nordt C. COVID-19, unemployment, and suicide. The Lancet Psychiatry 2020; 7: 389-390
80 de Leon J.. Evidence-based medicine versus personalized medicine: Are they enemies?. J Clin Psychopharmacol 2012; 32: 153-164
81 Persico AM, Arango C, Buitelaar JK. et al. Unmet needs in paediatric psychopharmacology: Present scenario and future perspectives. Eur Neuropsychopharmacol 2015; 25: 1513-1531
82 Sharma AN, Arango C, Coghill D. et al. BAP Position Statement: Off-label prescribing of psychotropic medication to children and adolescents. J Psychopharmacol 2016; 30: 416-421